Oxford, UK-based Vaccitech reportedly filed confidentially in the US for an initial public offering (IPO) on the Nasdaq. The company owns the technology used by AstraZeneca and the University of Oxford to develop their COVID-19 vaccine. At this time Vaccitech hasn’t priced its offering, although the report suggests they might sometime this month. Source: Biospace 7/4/2021